91 related articles for article (PubMed ID: 16047280)
1. [Drug transport in the respiratory epithelium].
Paul HB; Welte T; Groneberg DA
Pneumologie; 2005 Jul; 59(7):461-9. PubMed ID: 16047280
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport.
Groneberg DA; Fischer A; Chung KF; Daniel H
Am J Respir Cell Mol Biol; 2004 Mar; 30(3):251-60. PubMed ID: 14969997
[TBL] [Abstract][Full Text] [Related]
3. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.
Groneberg DA; Eynott PR; Döring F; Dinh QT; Oates T; Barnes PJ; Chung KF; Daniel H; Fischer A
Thorax; 2002 Jan; 57(1):55-60. PubMed ID: 11809991
[TBL] [Abstract][Full Text] [Related]
4. The renal type H+/peptide symporter PEPT2: structure-affinity relationships.
Biegel A; Knütter I; Hartrodt B; Gebauer S; Theis S; Luckner P; Kottra G; Rastetter M; Zebisch K; Thondorf I; Daniel H; Neubert K; Brandsch M
Amino Acids; 2006 Sep; 31(2):137-56. PubMed ID: 16868651
[TBL] [Abstract][Full Text] [Related]
5. Defining minimal structural features in substrates of the H(+)/peptide cotransporter PEPT2 using novel amino acid and dipeptide derivatives.
Theis S; Hartrodt B; Kottra G; Neubert K; Daniel H
Mol Pharmacol; 2002 Jan; 61(1):214-21. PubMed ID: 11752223
[TBL] [Abstract][Full Text] [Related]
6. Novel strategies of aerosolic pharmacotherapy.
Groneberg DA; Paul H; Welte T
Exp Toxicol Pathol; 2006 Jun; 57 Suppl 2():49-53. PubMed ID: 16580826
[TBL] [Abstract][Full Text] [Related]
7. Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake.
Groneberg DA; Nickolaus M; Springer J; Döring F; Daniel H; Fischer A
Am J Pathol; 2001 Feb; 158(2):707-14. PubMed ID: 11159208
[TBL] [Abstract][Full Text] [Related]
8. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours.
Rodriguez L; Batlle A; Di Venosa G; MacRobert AJ; Battah S; Daniel H; Casas A
Int J Biochem Cell Biol; 2006; 38(9):1530-9. PubMed ID: 16632403
[TBL] [Abstract][Full Text] [Related]
9. Identification of a potential substrate binding domain in the mammalian peptide transporters PEPT1 and PEPT2 using PEPT1-PEPT2 and PEPT2-PEPT1 chimeras.
Fei YJ; Liu JC; Fujita T; Liang R; Ganapathy V; Leibach FH
Biochem Biophys Res Commun; 1998 May; 246(1):39-44. PubMed ID: 9600064
[TBL] [Abstract][Full Text] [Related]
10. Expression, localisation and functional implications of the transporter protein PEPT2 in the upper respiratory tract.
Quarcoo D; Fischer TC; Heppt W; Lauenstein HD; Pilzner C; Welte T; Groneberg DA
Respiration; 2009; 77(4):440-6. PubMed ID: 19052442
[TBL] [Abstract][Full Text] [Related]
11. A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters.
Foltz M; Meyer A; Theis S; Demuth HU; Daniel H
J Pharmacol Exp Ther; 2004 Aug; 310(2):695-702. PubMed ID: 15051798
[TBL] [Abstract][Full Text] [Related]
12. Substrates of the human oligopeptide transporter hPEPT2.
Zhao D; Lu K
Biosci Trends; 2015 Aug; 9(4):207-13. PubMed ID: 26355221
[TBL] [Abstract][Full Text] [Related]
13. Importance of a small N-terminal region in mammalian peptide transporters for substrate affinity and function.
Döring F; Martini C; Walter J; Daniel H
J Membr Biol; 2002 Mar; 186(2):55-62. PubMed ID: 11944083
[TBL] [Abstract][Full Text] [Related]
14. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications.
Döring F; Walter J; Will J; Föcking M; Boll M; Amasheh S; Clauss W; Daniel H
J Clin Invest; 1998 Jun; 101(12):2761-7. PubMed ID: 9637710
[TBL] [Abstract][Full Text] [Related]
15. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.
Sugawara M; Huang W; Fei YJ; Leibach FH; Ganapathy V; Ganapathy ME
J Pharm Sci; 2000 Jun; 89(6):781-9. PubMed ID: 10824137
[TBL] [Abstract][Full Text] [Related]
16. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.
Knütter I; Wollesky C; Kottra G; Hahn MG; Fischer W; Zebisch K; Neubert RH; Daniel H; Brandsch M
J Pharmacol Exp Ther; 2008 Nov; 327(2):432-41. PubMed ID: 18713951
[TBL] [Abstract][Full Text] [Related]
17. [Molecular characteristics and tissue distribution of peptide transporters].
Han F; Le GW; Shi YH
Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):222-6. PubMed ID: 14628467
[TBL] [Abstract][Full Text] [Related]
18. Molecular changes to the rat renal cotransporters PEPT1 and PEPT2 due to ageing.
Alghamdi OA; King N; Andronicos NM; Jones GL; Chami B; Witting PK; Moens PDJ
Mol Cell Biochem; 2019 Feb; 452(1-2):71-82. PubMed ID: 30019300
[TBL] [Abstract][Full Text] [Related]
19. The PDZ domain protein PDZK1 interacts with human peptide transporter PEPT2 and enhances its transport activity.
Noshiro R; Anzai N; Sakata T; Miyazaki H; Terada T; Shin HJ; He X; Miura D; Inui K; Kanai Y; Endou H
Kidney Int; 2006 Jul; 70(2):275-82. PubMed ID: 16738539
[TBL] [Abstract][Full Text] [Related]
20. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls.
Brandsch M
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):887-905. PubMed ID: 19519280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
